Regulus Price To Sales Ratio vs Pb Ratio Analysis

RGLS Stock

USD 7.98 4.61 136.80%

Regulus Therapeutics financial indicator trend analysis is much more than just breaking down Regulus Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regulus Therapeutics is a good investment. Please check the relationship between Regulus Therapeutics Price To Sales Ratio and its Pb Ratio accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.

Price To Sales Ratio vs Pb Ratio

Price To Sales Ratio vs Pb Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regulus Therapeutics Price To Sales Ratio account and Pb Ratio. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Regulus Therapeutics' Price To Sales Ratio and Pb Ratio is 0.15. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Pb Ratio in the same time period over historical financial statements of Regulus Therapeutics, assuming nothing else is changed. The correlation between historical values of Regulus Therapeutics' Price To Sales Ratio and Pb Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Regulus Therapeutics are associated (or correlated) with its Pb Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pb Ratio has no effect on the direction of Price To Sales Ratio i.e., Regulus Therapeutics' Price To Sales Ratio and Pb Ratio go up and down completely randomly.

Correlation Coefficient

0.15

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Regulus Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Regulus Therapeutics sales, a figure that is much harder to manipulate than other Regulus Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Pb Ratio

Most indicators from Regulus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regulus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.At this time, Regulus Therapeutics' Tax Provision is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 98.6 M in 2025, whereas Selling General Administrative is likely to drop slightly above 13.2 M in 2025.

	2022	2023	2024	2025 (projected)
Interest Expense	688K	604K	158K	150.1K
Depreciation And Amortization	122K	227K	347K	329.7K

Interest Expense Depreciation And Amortization

Regulus Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Preferred Stock Total Equity	Total Current Assets	Short Term Debt
Total Assets		0.57	0.19	-0.31	0.86	0.06	0.22	0.06	-0.54	0.48	0.34	0.64	0.38	-0.06	0.76	-0.03	0.99	-0.16	0.95	0.18	0.48	-0.24	0.08	-0.23	1.0	0.2
Short Long Term Debt Total	0.57		0.14	0.41	0.24	0.28	0.61	0.13	-0.12	0.58	0.65	0.32	0.78	-0.58	0.68	-0.02	0.5	-0.73	0.6	0.33	0.18	-0.39	0.48	-0.02	0.53	0.58
Other Current Liab	0.19	0.14		0.07	0.47	-0.71	0.3	-0.86	-0.3	-0.59	0.45	0.3	0.23	0.37	0.11	-0.46	0.09	0.22	0.11	-0.69	0.61	0.73	-0.63	-0.71	0.17	0.18
Total Current Liabilities	-0.31	0.41	0.07		-0.43	0.2	0.51	-0.03	0.53	-0.03	0.53	-0.45	0.47	-0.35	-0.08	-0.18	-0.38	-0.3	-0.23	-0.08	-0.11	-0.05	0.29	0.02	-0.36	0.6
Total Stockholder Equity	0.86	0.24	0.47	-0.43		-0.35	0.03	-0.31	-0.66	0.05	0.19	0.68	0.11	0.27	0.56	-0.22	0.85	0.2	0.76	-0.29	0.61	0.16	-0.42	-0.55	0.87	0.1
Other Liab	0.06	0.28	-0.71	0.2	-0.35		0.27	0.86	0.22	0.8	0.14	-0.15	0.34	-0.54	0.01	0.57	0.08	-0.44	0.19	0.78	-0.26	-0.87	0.82	0.75	0.04	-0.14
Property Plant And Equipment Net	0.22	0.61	0.3	0.51	0.03	0.27		-0.14	-0.02	0.15	0.88	0.15	0.96	-0.29	0.24	0.25	0.1	-0.28	0.27	0.15	0.37	-0.12	0.35	-0.11	0.14	0.21
Current Deferred Revenue	0.06	0.13	-0.86	-0.03	-0.31	0.86	-0.14		0.18	0.83	-0.26	-0.15	-0.01	-0.51	0.05	0.46	0.13	-0.43	0.18	0.79	-0.39	-0.89	0.73	0.73	0.06	-0.13
Net Debt	-0.54	-0.12	-0.3	0.53	-0.66	0.22	-0.02	0.18		-0.13	-0.05	-0.97	-0.06	0.03	-0.13	-0.11	-0.51	-0.03	-0.49	0.18	-0.61	-0.04	0.35	0.33	-0.55	0.43
Retained Earnings	0.48	0.58	-0.59	-0.03	0.05	0.8	0.15	0.83	-0.13		0.1	0.24	0.35	-0.61	0.43	0.41	0.51	-0.64	0.59	0.81	-0.12	-0.93	0.77	0.55	0.47	0.04
Accounts Payable	0.34	0.65	0.45	0.53	0.19	0.14	0.88	-0.26	-0.05	0.1		0.18	0.87	-0.25	0.31	0.07	0.23	-0.23	0.38	0.05	0.43	-0.03	0.25	-0.16	0.28	0.32
Cash	0.64	0.32	0.3	-0.45	0.68	-0.15	0.15	-0.15	-0.97	0.24	0.18		0.22	-0.15	0.28	0.16	0.6	-0.13	0.59	-0.08	0.58	-0.04	-0.23	-0.33	0.64	-0.29
Non Current Assets Total	0.38	0.78	0.23	0.47	0.11	0.34	0.96	-0.01	-0.06	0.35	0.87	0.22		-0.41	0.43	0.23	0.28	-0.46	0.43	0.28	0.31	-0.24	0.46	-0.07	0.31	0.32
Non Currrent Assets Other	-0.06	-0.58	0.37	-0.35	0.27	-0.54	-0.29	-0.51	0.03	-0.61	-0.25	-0.15	-0.41		-0.1	-0.28	-0.03	0.84	-0.04	-0.46	0.18	0.54	-0.57	-0.31	-0.03	-0.12
Other Assets	0.76	0.68	0.11	-0.08	0.56	0.01	0.24	0.05	-0.13	0.43	0.31	0.28	0.43	-0.1		-0.21	0.76	-0.35	0.75	0.26	0.05	-0.24	0.23	-0.16	0.74	0.61
Long Term Debt	-0.03	-0.02	-0.46	-0.18	-0.22	0.57	0.25	0.46	-0.11	0.41	0.07	0.16	0.23	-0.28	-0.21		-0.02	-0.15	0.03	0.51	-0.12	-0.47	0.42	0.28	-0.05	-0.48
Cash And Short Term Investments	0.99	0.5	0.09	-0.38	0.85	0.08	0.1	0.13	-0.51	0.51	0.23	0.6	0.28	-0.03	0.76	-0.02		-0.13	0.94	0.22	0.38	-0.27	0.09	-0.19	0.99	0.19
Common Stock Shares Outstanding	-0.16	-0.73	0.22	-0.3	0.2	-0.44	-0.28	-0.43	-0.03	-0.64	-0.23	-0.13	-0.46	0.84	-0.35	-0.15	-0.13		-0.17	-0.44	0.32	0.5	-0.55	-0.21	-0.13	-0.32
Short Term Investments	0.95	0.6	0.11	-0.23	0.76	0.19	0.27	0.18	-0.49	0.59	0.38	0.59	0.43	-0.04	0.75	0.03	0.94	-0.17		0.31	0.47	-0.4	0.23	-0.08	0.94	0.2
Non Current Liabilities Total	0.18	0.33	-0.69	-0.08	-0.29	0.78	0.15	0.79	0.18	0.81	0.05	-0.08	0.28	-0.46	0.26	0.51	0.22	-0.44	0.31		-0.26	-0.84	0.93	0.75	0.17	-0.11
Other Current Assets	0.48	0.18	0.61	-0.11	0.61	-0.26	0.37	-0.39	-0.61	-0.12	0.43	0.58	0.31	0.18	0.05	-0.12	0.38	0.32	0.47	-0.26		0.2	-0.29	-0.33	0.46	-0.19
Other Stockholder Equity	-0.24	-0.39	0.73	-0.05	0.16	-0.87	-0.12	-0.89	-0.04	-0.93	-0.03	-0.04	-0.24	0.54	-0.24	-0.47	-0.27	0.5	-0.4	-0.84	0.2		-0.82	-0.71	-0.23	0.05
Total Liab	0.08	0.48	-0.63	0.29	-0.42	0.82	0.35	0.73	0.35	0.77	0.25	-0.23	0.46	-0.57	0.23	0.42	0.09	-0.55	0.23	0.93	-0.29	-0.82		0.72	0.05	0.12
Preferred Stock Total Equity	-0.23	-0.02	-0.71	0.02	-0.55	0.75	-0.11	0.73	0.33	0.55	-0.16	-0.33	-0.07	-0.31	-0.16	0.28	-0.19	-0.21	-0.08	0.75	-0.33	-0.71	0.72		-0.23	-0.29
Total Current Assets	1.0	0.53	0.17	-0.36	0.87	0.04	0.14	0.06	-0.55	0.47	0.28	0.64	0.31	-0.03	0.74	-0.05	0.99	-0.13	0.94	0.17	0.46	-0.23	0.05	-0.23		0.18
Short Term Debt	0.2	0.58	0.18	0.6	0.1	-0.14	0.21	-0.13	0.43	0.04	0.32	-0.29	0.32	-0.12	0.61	-0.48	0.19	-0.32	0.2	-0.11	-0.19	0.05	0.12	-0.29	0.18

Click cells to compare fundamentals

Regulus Therapeutics Account Relationship Matchups

Regulus Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	37.6M	68.5M	46.7M	30.8M	84.2M	61.8M
Short Long Term Debt Total	4.7M	7.1M	6.3M	2.4M	274K	260.3K
Other Current Liab	6.4M	4.9M	7.0M	7.0M	6.6M	6.1M
Total Current Liabilities	11.6M	5.2M	11.7M	8.5M	7.5M	10.9M
Total Stockholder Equity	26.0M	55.0M	33.3M	21.2M	76.4M	80.2M
Property Plant And Equipment Net	472K	2.8M	2.6M	2.5M	1.8M	3.4M
Current Deferred Revenue	2.6M	6K	3.4M	(589K)	(530.1K)	(503.6K)
Net Debt	(26.4M)	(53.3M)	(17.9M)	(21.4M)	(38.3M)	(40.2M)
Retained Earnings	(427.0M)	(454.9M)	(483.2M)	(513.2M)	(559.6M)	(531.6M)
Accounts Payable	535K	285K	175K	204K	947K	1.3M
Cash	31.1M	60.4M	24.2M	23.8M	38.5M	34.8M
Non Current Assets Total	874K	3.2M	2.6M	2.6M	1.8M	1.7M
Non Currrent Assets Other	487K	277K	291K	3.0M	3.5M	3.6M
Other Assets	0.0	24K	291K	1.0	0.9	0.86
Cash And Short Term Investments	31.1M	60.4M	39.2M	23.8M	75.8M	53.0M
Common Stock Shares Outstanding	3.5M	8.6M	15.3M	19.0M	56.3M	59.2M
Liabilities And Stockholders Equity	37.6M	68.5M	46.7M	30.8M	84.2M	61.8M
Non Current Liabilities Total	5.2M	8.3M	1.8M	1.1M	274K	260.3K
Other Current Assets	1.8M	1.8M	1.9M	1.4M	10.1M	10.6M
Other Stockholder Equity	453.0M	509.7M	516.5M	534.4M	635.9M	372.3M
Total Liab	11.6M	13.5M	13.4M	9.6M	7.8M	7.4M
Total Current Assets	36.7M	65.2M	44.1M	28.2M	82.3M	57.6M
Accumulated Other Comprehensive Income	(9.9M)	(4.4M)	(12K)	(1K)	50K	52.5K
Short Term Debt	4.7M	589K	4.5M	1.3M	1.2M	1.1M
Intangible Assets	125K	83K	62K	33K	25K	23.8K
Property Plant Equipment	921K	725K	2.8M	2.6M	2.3M	3.6M
Property Plant And Equipment Gross	472K	7.2M	7.0M	6.8M	6.4M	6.1M
Net Tangible Assets	19.7M	25.9M	28.9M	33.2M	29.9M	43.5M
Inventory	3.9M	3.3M	3.0K	3.0M	3.5M	3.6M
Common Stock	67K	146K	17K	20K	66K	57.8K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Regulus Stock Analysis

When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC